Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT06567717
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zinc — DRUG
    Zinc has not previously been investigated in the treatment of IPF.
  • Placebos for zinc and nicotinamide riboside — OTHER
    These will be identical in appearance to the active substances
  • Nicotinamide riboside — DRUG
    Nicotinamide riboside has not previously been investigated in the treatment of IPF.

Study Details

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF. Participants will: Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Key Dates

Start date
Nov 3, 2025
Status verified
Nov 2025
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Combination Supplements
    Zinc and nicotinamide riboside
  • Placebo Comparator: Placebo
    Placebo-controls for both zinc and nicotinamide riboside

Primary Outcome Measure

Feasibility of Retention [ Time Frame: From study activation to 78 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars-SinaiLos AngelesCalifornia90048
Tanzira Zaman, MD
[email protected]
424-314-0585

Find similar trials in Los Angeles, CA

By research site
Cedars-Sinai· Los Angeles, CA

Related Studies